Oct 19 (Reuters) - Swiss online drug retailer DocMorris
DOCM.S on Thursday narrowed down the higher end of its annual
core loss forecast, citing a weaker development in the paper
prescription business.
The company, which relies heavily on the German market after
it sold its Swiss business earlier this year, sees adjusted core
loss of 30 million to 40 million Swiss francs ($33.4 million to
$44.5 million) in 2023, compared to the previous range of 20-40
million.
($1 = 0.8990 Swiss francs)
(Reporting by Tristan Veyet and Mateusz Dobrzyniewski in
Gdansk; editing by Milla Nissi)
((Tristan.Chabba@thomsonreuters.com;))